Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness
May 23, 2016 at 11:46 AM EDT
Chardan Capital Markets has started coverage of Asterias Biotherapeutics Inc (NYSE: AST) with a Buy rating and $5.50 price target, ...
